Comparison of NSCLC patient groups with activated EGFR mutations treated with three different tyrosine-kinase inhibitors (TKI): Real-life data from the Czech Republic
| Autor: | František Salajka, Libor Havel, Renata Chloupková, Leona Koubková, Jana Krejčí, Zdeněk Merta, Marketa Cernovska, Vítězslav Kolek, Andrea Benejová, Monika Šatánková, Dimka Sixtová, Milada Zemanova, Jaromír Roubec, Jana Skřičková, Miloš Pešek, Marcela Tomíšková, Michal Hrnčiarik, Karel Hejduk, Ivona Grygárková |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Czech
Oncology medicine.medical_specialty biology business.industry Afatinib Real life data language.human_language respiratory tract diseases Exact test Gefitinib Internal medicine Statistical significance medicine biology.protein language Epidermal growth factor receptor business Tyrosine kinase medicine.drug |
| Zdroj: | Lung Cancer. |
| Popis: | Background and Aim: From October 2013 there is a possibility to treat patients with NSCLC and with activated epidermal growth factor receptor (EGFR) mutations with three TKI (afatinib, eriotinib, gefitinib) in the Czech Republic. We have tried to find differences among patient groups treated with single TKI in 1st line of treatment. Patients and methods: As data source we used the TULUNG registry, which is focused on the data collection of patients with NSCLC treated with target therapy in the Czech Republic. We analysed 232 patients (gefitinib - 115 patients, afatinib - 77 patients, eriotinib - 40 patients.). Statistical significance was assessed using the Fisher's exact test or Kruskal-Wallis test (a=0.05). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|